Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee

Some Endocrinologic and Metabolic Drugs Advisory Committee members said a REMS is sufficient, but others worried that proposed risk management plans were not proven effective.

FDA Advisory Committee Feature image

US FDA advisory committee members split on whether Sanofi and Lexicon Pharmaceuticals Inc.'s proposed type 1 diabetes treatment sotagliflozin should be approved amid questions about how to manage the risk of diabetic ketoacidosis.

The 8-8 vote by the Endocrinologic and Metabolic Drugs Advisory Committee Jan. 17 included dueling recommendations that a Risk Evaluation...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers